

Support for new claims 96-98, which are directed to pharmaceutical compositions of dendritic cells, are supported by original claims 43-45 and 54-57.

Support for new claim 99, which is directed to a mixed culture of activated dendritic cells and T cells, can be found throughout the specification (*See*, e.g. page 11, lines 31-35 through page 12, line 1).


Support for new claim 100-101, which are directed to pharmaceutical compositions comprising a dendritic cell-modified antigen, can be found throughout the specification (*See*, e.g. page 13, lines 3-5) and original claim 45.

None of these amendments constitute new matter and applicants respectfully requests their entry into the application.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account 13-4500, Order No. 2016-4000US5.  
A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: December 4, 1998

By:   
Kenneth H. Sonnenfeld  
Reg. No. 33,285

Mailing Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 (FAX)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on 12/4/98

Sybil A. Lombillo  
